SMS Terms & Conditions
Parents and Caregivers:
By agreeing to receive marketing messages, you consent to receive text messages on behalf of the Sanofi Health News Program at the mobile telephone number(s) that you provide. Text “STOP”, “SMSSTOP”, “DNPSTOP”, “TEXTOUT”, “DPOUT”, or “DEOUT” to 43601 to opt out at any time. Text “HELP”, “SMSHELP”, “DNPHELP”, “TEXTHELP”, “DPHELP”, or “DEHELP” to 43601 for help at any time. For additional support call 1-855-239-3678. Message and data rates may apply for any messages sent to you from us and to us from you. Messaging frequency varies. If you have any questions about your text plan or data plan, it is best to contact your wireless provider. Participating Carriers include all U.S.-Based Carriers. Messages may be delayed or undelivered for various reasons. Sanofi, Eversana Intouch, carriers, and any service providers utilized by Eversana Intouch to send messages are not liable for delayed or undelivered messages. If you have questions regarding privacy, please read our Privacy Policy.
Healthcare Professionals:
By agreeing to receive marketing messages, you consent to receive text messages on behalf of the Beyfortus (nirsevimab-alip) Alerts Program at the mobile telephone number(s) that you provide. Text “STOP”, “SMSSTOP”, “DNPSTOP”, “TEXTOUT”, “DPOUT”, or “DEOUT” to 91062 to opt out at any time. Text “HELP”, “SMSHELP”, “DNPHELP”, “TEXTHELP”, “DPHELP”, or “DEHELP” to 91062 for help at any time. For additional support call 1-855-239-3678. Message and data rates may apply for any messages sent to you from us and to us from you. Messaging frequency varies. If you have any questions about your text plan or data plan, it is best to contact your wireless provider. Participating Carriers include all U.S.-Based Carriers. Messages may be delayed or undelivered for various reasons. Sanofi, Eversana Intouch, carriers, and any service providers utilized by Eversana Intouch to send messages are not liable for delayed or undelivered messages. If you have questions regarding privacy, please read our Privacy Policy.
若您的孩子對nirsevimab-alip或Beyfortus的任何成分有嚴重的過敏反應史，請勿接種Beyfortus。
在您的孩子接種Beyfortus之前，請將孩子的所有醫療狀況告知您的醫療保健人員，包括如果孩子：
- 曾對Beyfortus出現反應。
- 曾發生出血或瘀青問題。若您的孩子有容易出血或瘀青的問題，可能因注射導致傷害。
請告知醫療保健人員關於孩子的所有用藥情況，包括處方和非處方藥物，維他命以及草本保健品。如果嬰兒在同一個RSV好發季節已經接種Beyfortus，請勿再使用palivizumab藥物。
使用Beyfortus藥物曾發生過嚴重的過敏反應。若您的孩子有以下嚴重過敏反應的徵兆或症狀，請立即尋求 醫療協助：
- 臉部、嘴巴或舌頭腫脹
- 吞嚥或呼吸困難
- 無意識
- 皮膚、嘴唇或指甲內的顏色呈藍色
- 肌肉無力
- 嚴重紅疹、蕁麻疹或搔癢
Beyfortus最常見的副作用為紅疹與注射部位疼痛、腫脹或出現硬塊，但Beyfortus仍可能引發其他副作用。若您對副作用有任何疑慮，請聯繫醫療保健人員。
點擊此處，了解更多關於Sanofi打擊偽藥的承諾。
Beyfortus為處方藥物，用於幫助以下群體預防因感染呼吸道融合病毒（RSV）而導致的嚴重肺部疾病：
- 正值或進入第一個RSV好發季節時出生的新生兒或未滿1歲的嬰兒。
- 在第二個RSV季節期間仍然容易罹患嚴重RSV疾病的24個月以下兒童。
